Mode
Text Size
Log in / Sign up
N/A N=55 Basic Science

Coherence Imaging of the Cervical Epithelium

Cervical Epithelia

Enrolled (actual)
55
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcome: Primary: Number of Patients With Interferometric Data Acquired From Cervical Epithelium — 3; 41 patients

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
mLCI Device (Device)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Duke University
Primary completion
Oct 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Interferometric Data Acquired From Cervical Epithelium
3; 41
SECONDARY
Number of Patients With Automated Classification of Cervical Epithelium
36
SECONDARY
Number and Frequency of Adverse Events
0; 0

Summary

The purpose of this study is to develop a multiplexed low coherence interferometry (mLCI) endoscopic probe for mapping the epithelial types of the cervix. This vaginal mLCI probe will obtain optical measurements from the cervix. These measurements can be used to create a map of the surface cells that distinguishes ectocervical epithelia, endocervical epithelia, and the squamocolumnar junction (t-zone), which is the region where cervical dysplasia is most likely to occur.

Eligibility Criteria

Inclusion Criteria

  • able to provide informed consent
  • willing to abstain from sexual intercourse for at least 24 hours before study visit

Exclusion Criteria

  • pregnant
  • using an intrauterine device (IUD)
  • have a current gynecological infection or discharge
  • have had any cervical surgery
  • had medical or cosmetic surgery involving the reproductive organs or genitals within the past 6 months
  • currently enrolled in any research studies involving the application of vaginal formulations
  • employed or supervised by the study investigators
  • have any other condition, that, in the opinion of the study clinician, would contraindicate participation in the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02903394). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search